Clinical Trials

BLU-285-3101

Link : https://www.clinicaltrials.gov/ct2/show/NCT04773782
Status : RECRUITING
Population : R/R solid tumor, including CNS tumors, with a mutation in PDGFRA and/or KIT
Description : This is a Phase 1/2, multicenter, open-label trial of avapritinib in participants 2 to < 18 years of age with advanced relapsed/refractory (R/R) solid tumors, including central nervous system (CNS) tumors, that harbor a PDGFRA and/or KIT mutation (including non-synonymous point mutations, insertions, and deletions) or amplification, or DMG-H3K27a who have no available curative treatment options. This is a single-arm trial in which all participants will receive avapritinib. The study consists of 2 parts: dose confirmation, safety, and PK (Part 1) and initial efficacy, safety, and PK at the Part 2 recommended dose (Part 2).
PI : D. Morgenstern
Centers Opened : SickKids
Phase : I/II
IIST/Pharma : Pharma